The purpose of this research project is to assess the glycaemic controlling effects of consuming BSG and bio-transformed BSG-containing biscuits and its underlying gut - related mechanism in adults with MetS using in-vivo setting.
This is a double-blind, randomised, parallel experiment, all subjects (38 adults in Singapore with MetS) will complete a 12-week intervention period. Subjects will be randomly assigned to consume their habitual diet with biscuit that either does not contain or contains autoclaved BSG or bio-transformed BSG for 12 weeks. Throughout the intervention, subjects will be assessed for glucose, insulin, lipid and amino acid responses, biomarkers of gut health, and as well as other markers of health.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Enrollment
38
Consumption of plain biscuits everyday during intervention period.
Consumption of autoclaved BSG-containing biscuits everyday during intervention period.
Consumption of bio-transformed BSG-containing biscuits everyday during intervention period.
NUS Department of Food Science & Technology
Singapore, Singapore
Change in blood glucose concentration
Glucose concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in insulin concentration
Insulin concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in blood triglyceride concentration
Triglyceride concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in blood cholesterol concentration
Total cholesterol concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in blood Low-density Lipoprotein-cholesterol (LDL) concentration
Low-density Lipoprotein-cholesterol concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in High-density Lipoprotein-cholesterol (HDL) concentration
High-density Lipoprotein-cholesterol concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in Hemoglobin A1c (HbA1c) concentration
Hemoglobin A1c (HbA1c) concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in C-reactive protein concentration
C-reactive protein concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Change in IL-6 concentration
IL-6 concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in TNF-alpha concentration
TNF-alpha concentration in the blood will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in gut microbiome composition
Gut microbiome composition in the fecal will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in short chain fatty acids concentration
Short chain fatty acids concentration in the fecal will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in bile acid concentration
Bile acid concentration in the fecal will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in zonulin concentration
Zonulin concentration in the fecal will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in calprotectin levels
Calprotectin concentration in the fecal will be measured
Time frame: Every 12 week (week 0 and week 12)
Change in appetite assessed by visual analogue scale
Visual analogue scale will be used to assess appetite.
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)
Change in sleep quality by questionnaire
Questionnaire will be used to assess sleep quality
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)
Change in weight and height
Weight (in kilograms) and height (in meters) will be combined to report BMI in kg/m\^2
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)
Change in blood pressure
Systolic and diastolic blood pressure (in mmHg) will be measured by a blood pressure monitor.
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)
Change in skin advanced glycation end products status
Skin advanced glycation end products status will be measured by a monitor.
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)
Change in dietary
Questionnaire will be used to record dietary
Time frame: Every 4 week (week 0, week 4, week 8 and week 12)